MNM. V. Natrusova

M. V. Natrusova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


M. V. Natrusova has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Secondary Hemophagocytic Lymphohistiocytosis in a Child with Myeloid Sarcoma: A Literature Review and Case Report

    by G. O. Bronin, A. A. Bystrova, K. L. Kondratchik, E. A. Burtsev, M. V. Natrusova, Galimat Abdulkhalikovna Radjabova, E. V. Kumirova, A. M. Kovrigina, T. T. Valiev

    Вторичный гемофагоцитарный лимфогистиоцитоз (ГЛГ) является редким и опасным осложнением злокачественных новообразований у детей. Сложность подобных клинических ситуаций заключается в том, что вторичный ГЛГ затрудняет диагностику и своевременное начало лечения опухолевого заболевания. В настоящей публикации представлено собственное клиническое наблюдение вторичного ГЛГ у ребенка в возрасте 2 лет и 5 мес. При детальном обследовании больной диагностирована миелоидная саркома с поражением костей черепа и лицевого скелета с формированием множественных мягкотканных объемных образований. Предпринятые попытки купирования симптомов вторичного ГЛГ и программное лечение миелоидной саркомы не увенчались успехом. Учитывая высокую летальность и недостаточную эффективность существующих подходов к лечению вторичных ГЛГ, представляется крайне важным изучение и внедрение новых терапевтических стратегий с включением таргетных препаратов.

  • Open Access

    Tandem hematopoietic stem cell transplantation in children with solid tumors in the Russian Federation: results of a retrospective multicenter study

    by D. S. Smirnova, K. I. Kirgizov, I. V. Kazantsev, S. A. Kulyova, P. S. Tolkunova, Yu. V. Dinikina, A. Yu. Smirnova, S. I. Lapaeva, T. Z. Aliev, G. B. Sagoyan, et al.

    Relevance. Despite the overall decline in the use of auto-HSCT, there remains a need for treatment intensification in pediatric patients with highrisk solid tumors. Tandem auto-HSCT represents a promising approach to improve therapeutic efficacy, but its toxicity and impact on long-term outcomes require further investigation, particularly in the Russian patient population.The aim of study – to evaluate the feasibility, toxicity, and long-term outcomes of tandem autologous hematopoietic stem cell transplantation (auto-HSCT) in children with high-risk solid malignant neoplasms in the Russian Federation.Materials and methods. This retrospective multicenter study included 108 (100 %) pediatric patients (median age – 2 years) with solid malignant neoplasms who underwent tandem high-dose chemotherapy with auto-HSCT at 9 centers in the Russian Federation (2004–2024). Main diagnoses included brain tumors – n = 66 (61.1 %), germ cell tumors – n = 25 (23 %), and neuroblastoma – n = 12 (11.1 %). Toxicity was assessed using CTCAE v5.0 criteria, and survival analysis was performed using the Kaplan–Meyer method.Results. The most common complications were febrile neutropenia (88.9 %) and oropharyngeal mucositis (87.1 %), with severe toxicities (Grade 3–4) being rare. The 3-year overall survival was 72.2 %, and event-free survival was 62.7 %.Conclusion. The study demonstrated that tandem auto-HSCT is a feasible procedure with manageable toxicity. These findings suggest the potential of tandem auto-HSCT for children with high-risk solid tumors, though further prospective studies with long-term outcome assessments are needed to define optimal indications.


  • Open Access

    Acute myeloid leukemia with translocations involving the KMT2A gene in twins as a model for the study of leukemogenesis: clinical case reports and genetic characteristics

    by Z. Z. Askerova, E. A. Zerkalenkova, S. A. Lebedeva, K. S. Iskakova, D. A. Venyov, U. N. Petrova, D. D. Baydildina, D. N. Balashov, G. O. Bronin, I. Ya. Tomilin, et al.

    Familial cases of acute leukemia in children are very rare and are mainly reported in cases of genetically determined predisposition syndromes (mutations in the RUNX1, ETV6, ANKRD26, GATA2, SAMD9/SAMD9L, CEBPA genes) which have been well characterized in the last 15 years. In twins, leukemia is even more rare and is of particular interest for the study of leukemogenesis patterns and evolution of leukemic subclones. Here, we report about three pairs of twins: in one pair, KMT2A-r-leukemia was diagnosed simultaneously, while in the other two cases the second child remained healthy despite the development of KMT2A-r-leukemia in their twin. The patients’ parents gave consent to the use of their children's data, including photographs, for research purposes and in publications.

  • Open Access

    ОМЛ с транслокациями, вовлекающими ген КМТ2А, у близнецов как модель для исследования лейкемогенеза: описание клинических случаев и генетические характеристики.

    by Захра Зауровна Аскерова, Елена Александровна Зеркаленкова, Светлана Александровна Лебедева, Кристина Станиславовна Искакова, Дмитрий Александрович Венёв, Ульяна Николаевна Петрова, Дина Дамировна Байдильдина, Дмитрий Николаевич Балашов, Глеб Олегович Бронин, Иван Яковлевич Томилин, et al.

    Pediatric Hematology/Oncology and Immunopathology | Peer-rewiev medical journal Вопросы гематологии/онкологии и иммунопатологии в педиатрии | Научный рецензируемый журнал

  • Open Access

    Fecal microbiota transplantation for the treatment of intestinal diseases after allogeneic hematopoietic stem cell transplantation in children

    by G. Z. Seregin, Yu. A. Bespyatykh, A. V. Gospodarik, M. Yu. Kirillov, L. V. Ogneva, S. V. Zhilina, E. A. Burtsev, A. E. Burya, I. O. Vlasova, M. R. Zhuravel, et al.

    Fecal microbiota transplantation (FMT) is a promising therapy for a variety of diseases involving the gastrointestinal (GI) tract. The purpose of our study is to evaluate the effectiveness of FMT for the treatment of different GI complications after allogenic hematopoietic stem cell transplantation (steroid-refractory and steroid-dependent graft versus host disease (SR/ SD GVHD) and infectious enterocolitis) in children from 1.5 to 18 years old. The study was approved by the Local Ethics Committee of the Morozov Children's Clinical Hospital of the Department of Health of Moscow (No. 176 dated 24.05.2022). The patients' parents gave their informed consent to the participation of their children in the study and the publication of the study results. SR/SD GVHD group included 14 patients and GI infections group – 11 patients. In total, 38 FMTs were performed. Eleven children underwent repeated FMTs due to the lack of effect after the first FMT. The resolution of diarrhea followed by the withdrawal of corticosteroids was recorded in 11 out of 14 patients with SR/SD GVHD. Ten out of 11 patients with GI infections also achieved relief of diarrhea. The clinical effect correlated with changes in the microbiome structure: for both groups of patients, the median proportion of normal microbiota before FMT was 6%, after FMT – 92% (p = 0.043). The median number of different taxa for both groups of patients before and after FMT were 3 and 10 taxa, respectively (p = 0.0016).


  • IMMUNOTHERAPY WITH ANTI-GD2 MONOCLONAL ANTIBODIES IN HIGH-RISK NEUROBLASTOMA PATIENTS ON AN OUTPATIENT BASIS

    by M.V. Natrusova, G.O. Bronin, B.M. Kurmanov, V.V. Konstantinova, A.V. Lifshits, E.A. Zhuravel, N.V. Bronina, E.A. Burtsev, E.V. Kumirova, Moscow Morozov Children’s City Clinical Hospital

    Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. Prior to the introduction of intensive multimodal therapy, overall survival (OS) in patients with high-risk NB was below 15%. The addition of immunotherapy with dinutuximab beta in post-consolidation to multimodal treatment can increase the 5-year event-free survival rate for patients with high-risk NB up to 56.6%, and the 5-year OS up to 73.2%. The purpose of the research was to study the efficacy and safety of dinutuximab beta therapy in high-risk NB patients. Materials and methods used: the study included 8 pediatric patients with high-risk NB who had been treated with dinutuximab beta immunotherapy during postconsolidation on the basis of the Morozov Children’s City Clinical Hospital (Moscow, Russia) in 2020 to 2022. In case a patient's vital parameters normalization coupled with the absence of the need for accompanying therapy for 24 hours in a hospital, the patient was then considered as a candidate for outpatient treatment with possible no need for admission in the hospital. Results: 6 patients (75%) completed the full course of therapy with dinutuximab beta. The course of immunotherapy was not completed in 2 patients due to further progression of the disease. The most common adverse events were recorded as follows: pain (100%), fever (100%), diarrhea (62.5%), edematous syndrome (37.5%), allergic reactions (25%), hematological toxicity (25%). The period of time to becoming the candidates for outpatient treatment was 10.38±2.56 days for the 1st cycle of therapy and 2.67±1.63 days for the last, 5th cycle of the immunotherapy. In 6 out of 8 cases described the immunotherapy with dinutuximab beta allowed maintaining the response to treatment achieved after the end of consolidation preventing further development of the disease. The overall good tolerance to the drug made it possible to carry out the immunotherapy on an outpatient basis using microinfusing pump. Conclusion: an adequate route of administration and accompanying treatment make dinutuximab beta toxicity profile sufficient for outpatient management of patients with high-risk NB.

  • IMMUNOTHERAPY WITH ANTI-GD2 MONOCLONAL ANTIBODIES IN HIGH-RISK NEUROBLASTOMA PATIENTS ON AN OUTPATIENT BASIS

    by M.V. Natrusova, G.O. Bronin, Moscow Morozov Children’s City Clinical Hospital, B.M. Kurmanov, V.V. Konstantinova, A.V. Lifshits, E.A. Zhuravel, N.V. Bronina, E.A. Burtsev, E.V. Kumirova

    Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. Prior to the introduction of intensive multimodal therapy, overall survival (OS) in patients with high-risk NB was below 15%. The addition of immunotherapy with dinutuximab beta in post-consolidation to multimodal treatment can increase the 5-year event-free survival rate for patients with high-risk NB up to 56.6%, and the 5-year OS up to 73.2%. The purpose of the research was to study the efficacy and safety of dinutuximab beta therapy in high-risk NB patients. Materials and methods used: the study included 8 pediatric patients with high-risk NB who had been treated with dinutuximab beta immunotherapy during postconsolidation on the basis of the Morozov Children’s City Clinical Hospital (Moscow, Russia) in 2020 to 2022. In case a patient's vital parameters normalization coupled with the absence of the need for accompanying therapy for 24 hours in a hospital, the patient was then considered as a candidate for outpatient treatment with possible no need for admission in the hospital. Results: 6 patients (75%) completed the full course of therapy with dinutuximab beta. The course of immunotherapy was not completed in 2 patients due to further progression of the disease. The most common adverse events were recorded as follows: pain (100%), fever (100%), diarrhea (62.5%), edematous syndrome (37.5%), allergic reactions (25%), hematological toxicity (25%). The period of time to becoming the candidates for outpatient treatment was 10.38±2.56 days for the 1st cycle of therapy and 2.67±1.63 days for the last, 5th cycle of the immunotherapy. In 6 out of 8 cases described the immunotherapy with dinutuximab beta allowed maintaining the response to treatment achieved after the end of consolidation preventing further development of the disease. The overall good tolerance to the drug made it possible to carry out the immunotherapy on an outpatient basis using microinfusing pump. Conclusion: an adequate route of administration and accompanying treatment make dinutuximab beta toxicity profile sufficient for outpatient management of patients with high-risk NB.

  • Open Access

    Approaches to the treatment of a multisystem form of juvenile xanthogranuloma with central nervous system lesion

    by M. V. Natrusova, E. A. Burtsev, N. V. Bronina, D. S. Osipova, D. A. Evseev, E. V. Seliverstova, G. O. Bronin, M. A. Maschan, Е. V. Kumirova

    Relevance. Juvenile xanthogranuloma (JXG) is the most common form of non-Langerhans cell histiocytic disorder. Cutaneous forms of the disease spontaneously regress within a few years, while systemic forms of JXG require treatment and may pose a threat to the lives of patients. Due to the lack of unified approach to the treatment of multisystem forms of JXG, the question of effective therapy tactics remains unresolved. The most common approach is to use Langerhans cell histiocytosis (LCH) treatment regimens for JXG. With the understanding of the leading role of mutations in the MEK-ERK signaling pathway in the pathogenesis of JXG, targeted therapy, BRAF- and MEK-inhibitors, are increasingly being considered in the treatment of JXG.Clinical cases. We present two cases of multisystem JXG with central nervous system (CNS) lesions. The first patient with CNS and skin lesions was treated with chemotherapy, developed for the treatment of multisystem LCH, which allowed us to obtain an effect “active disease better” (AD better). The second JXG patient with brain, lungs, bones, and adrenal gland lesions, combined targeted therapy with BRAF- and MEKinhibitors, vemurafenib and cobimetinib, resulted in a “non active disease” (NAD) effect.Conclusion. Multisystem form of JXG with CNS involvement is a rare oncological disease, the therapy of which has not been developed. With the introduction of molecular genetic profiling technology, it became possible to obtain NAD effect using targeted therapy.


  • Open Access

    Anti-GAD encephalitis in a child with beta-thalassemia after allogeneic hematopoietic stem cell transplantation

    by N. V. Bronina, I. O. Schederkina, B. M. Kurmanov, E. A. Burtsev, M. V. Natrusova, G. O. Bronin

    Glutamic acid decarboxylase (GAD) is an intracellular enzyme expressed in brain neurons and insulin-secreting β-cells of the pancreas. Anti-GAD-anitibodies are associated with type 1 diabetes mellitus, limbic encephalitis, cerebellar ataxia, temporal autoimmune epilepsy, and rigid man syndrome. We present a rare clinical case of anti-GAD-anitibodies- associated immune encephalitis in a child with beta-thalassemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT).A 3-year-old boy diagnosed with beta-thalassemia underwent allo-HSCT from a 9/10 compatible unrelated donor. The macrophage activation syndrome occurred during the early post-transplantation period. The seizure with a focal onset happened on day +65. The cytotoxic edema in the region of the left hippocampus without signs of accumulation of a contrast agent was revealed at the magnetic resonance imaging of the brain. Pleocytosis, increase in protein levels, infection and antibodies to receptors and synaptic proteins of neurons were not detected at the analysis of cerebrospinal fluid. A positive titer to anti-GAD-anitibodies was detected in the blood – 315.82 IU/ml (the norm is up to 10 IU/ml). The child was treated with cyclophosphamide 750 mg/m2, rituximab 375 mg/m2, and tocilizumab 8 mg/kg. The cytotoxic edema in the left hippocampus regressed at the control magnetic resonance imaging on day +117.Infectious, immune and toxic agents can cause the damage of central nervous system in patients after allo-HSCT. The mechanism of immune damage to the central nervous system S in such patients is still being studied and may be different: expansion of autoreactive lymphocytes due to failure of T-cell regulation due to chemo- or immunosuppressive therapy, “passenger lymphocyte” syndrome, violation of T-cell regulation due to the course of infectious complications and acute graft versus host disease.In a series of diagnostic searches in patients with central nervous system lesions after allo-HSCT, it is necessary to include immune damage to the nervous system. Diagnosis of such conditions is a difficult task due to comorbidity and multicomponent accompanying therapy, including immunosuppressive therapy, administered to patients.


  • Open Access

    Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC

    by I. А. Dzhanyan, М. V. Natrusova, V. V. Breder

    Introduction. HCC is a challenge for clinical oncology. 1-year mortality for advanced HCC accounts for 66% in theRussian Federation. The results obtained in the combined Atezolizumab and Bevacizumab therapy in the advanced HCC cases are reported.Objective. To assess efficacy and safety of anti-VEGF/PD-L1 Atezolizumab plus Bevacizumab therapy in 20 unresectable HCC patients.Materials and methods. This analyses carried out in Blokhin National Cancer Research Centre included 20 patients with unresectable HCC treated with the first-line Atezolizumab (1200 mg) and Bevacizumab (15 mg/kg) once every 21 days, 11 patients participated into the global open-label phase 3 trial IMbrave150 23,24 (NCT03434379 / YO40245; Sponsor of study F. Hoffmann-La Roche, Ltd). The therapy was discontinued in cases of tumor progression or intolerant toxicity. The efficacy was evaluated according to RECICT 1.1 criteria. The results were analyzed and visualized on the basis of statistical calculations R 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria). Descriptive statistics for quantitative variables are presented as mean (standard devia[1]tion) and median (lower and upper quartiles), for categorial variables as absolute number of observations (%). To compare quan[1]titative variables (AFP level) in progress Wilcoxon test was used. The differences were considered statistically significant with p < 0.05. Overall survival (OS) and progression-free survival (PFS) data were evaluated according to Kaplan-Meier methodology.Results and discussion. Median follow up was 9.3 months (quartile 1–3: 6.0–14.4) for 20 patients. Median progression free sur[1]vival was 14.9 months (lower bound, 95% CI, 9.0 months, upper bound NA). 12–month progression-free survival rate from the fixed date of the initial therapy was 56.2% (95% CI: 34.4–91.8%). One-year survival for 20 patients from the fixed date of the initial therapy was 70.0% (95% CI: 49–100). Treatment resulted in objective response (partial regression) in 3 (15%) pts, stable disease in 13 (65.0%) and progression in 4 (20.0%), patients. 35% of patients experienced Gr 3–4 adverse events with Gr3–4 arterial hypertension was the most common one in 20%. In 1 case esophageal varices hemorrhage Gr3 took place.Conclusion. Atezolizumab and Bevacizumab seems to be highly efficient in advanced HCC.